Stay updated with breaking news from Biosimilars Today. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Although most clinicians surveyed are unopposed to prescribing adalimumab biosimilars, hesitancies surrounding prescribing practices and an uncertainty of cost savings remains.
A survey of gastroenterologists, dermatologists, and rheumatologists found Amjevita had the most recognition, followed by Cyltezo, the only interchangeable biosimilar on the US market.
/PRNewswire/ -- AbbVie's Humira (adalimumab) is the world's best selling drug, but the entry of biosimilar challengers, with Amgen's Amjevita being the first...
/PRNewswire/ -- Ophthalmologists saw the entry of the first biosimilars into the armamentarium in 2022 with the launch of Biogen and Samsung's Byooviz and...
/PRNewswire/ -- Ophthalmologists saw the entry of the first biosimilars into the armamentarium in 2022 with the launch of Biogen and Samsung's Byooviz and...